
    
      To evaluate the safety, efficacy and pharmacokinetics/ pharmacodynamics of LB03002 in the
      treatment of growth failure in children with growth hormone deficiency (GHD) and to determine
      the dose for a subsequent phase IIIb BPLG-004 study
    
  